C-FLIP Polyclonal Antibody

Rabbit Anti-c-FLIP Polyclonal Antibody

Product Specifications

Background

The protein encoded by CFLAR (CASP8 and FADD like apoptosis regulator) is a regulator of apoptosis and is structurally similar to caspase-8. However, the encoded protein lacks caspase activity and appears to be itself cleaved into two peptides by caspase-8. Several transcript variants encoding different isoforms have been found for CFLAR, and partial evidence for several more variants exists.

CAS Number

9007-83-4

Product Name Alternative

CFLAR; CASH; CASP8AP1; CLARP; MRIT; CASP8 and FADD-like apoptosis regulator; Caspase homolog; CASH; Caspase-eight-related protein; Casper; Caspase-like apoptosis regulatory protein; CLARP; Cellular FLICE-like inhibitory protein; c-FLIP; FAD

Gene ID

8837

Accession Number

O15519

Reactivity

Human, Mouse

Immunogen

Synthesized peptide derived from the Internal region of human c-FLIP at AA range: 150-230

Clonality

Polyclonal

Tag

CASP8 and FADD-like apoptosis regulator

Applications

WB, IHC, IF, ELISA

Purification Method

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration

1 mg/ml

Molecular Weight

55kD

Precautions

The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Shipping Conditions

Gel pack with blue ice.

Storage Conditions

Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.

Notes

C-FLIP Polyclonal Antibody detects endogenous levels of c-FLIP protein.

Observed Molecular Weight

Formulation

Liquid solution

Buffer pH

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Applications Notes

Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-1:2000; IHC 1:100-1:300; ELISA 1:20000; IF 1:50-200